Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio P S Santos

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
JAK2 inhibitors: are they the solution?Fabio P S Santos, Srdan Verstovsek
Hematology/Oncology Clinics of North America|September 27, 2012
Therapy with JAK2 inhibitors for myeloproliferative neoplasmsFabio P S Santos, Srdan Verstovsek
Hematology (Amsterdam, Netherlands)|April 18, 2012
Breakthroughs in myeloproliferative neoplasmsFabio P S Santos, Srdan Verstovsek
Blood Reviews|November 25, 2010
JAK2 inhibitors: what's the true therapeutic potential?Fabio P S Santos, Srdan Verstovsek
Current Opinion in Hematology|February 7, 2013
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?Fabio P S Santos, Srdan Verstovsek
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?Fabio P S Santos, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|May 27, 2014
Efficacy of ruxolitinib for myelofibrosisFabio P S Santos, Srdan Verstovsek
Leukemia & Lymphoma|December 19, 2009
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitorsFabio P S Santos, Farhad Ravandi
Expert Opinion on Pharmacotherapy|September 21, 2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemiasFabio P S Santos, Jorge Cortes
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?Fabio P S Santos, Susan O'Brien
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
JAK2 inhibitors: are they the solution?Fabio P S Santos, Srdan Verstovsek
Hematology/Oncology Clinics of North America|September 27, 2012
Therapy with JAK2 inhibitors for myeloproliferative neoplasmsFabio P S Santos, Srdan Verstovsek
Hematology (Amsterdam, Netherlands)|April 18, 2012
Breakthroughs in myeloproliferative neoplasmsFabio P S Santos, Srdan Verstovsek
Blood Reviews|November 25, 2010
JAK2 inhibitors: what's the true therapeutic potential?Fabio P S Santos, Srdan Verstovsek
Current Opinion in Hematology|February 7, 2013
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?Fabio P S Santos, Srdan Verstovsek
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?Fabio P S Santos, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|May 27, 2014
Efficacy of ruxolitinib for myelofibrosisFabio P S Santos, Srdan Verstovsek
Leukemia & Lymphoma|December 19, 2009
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitorsFabio P S Santos, Farhad Ravandi
Expert Opinion on Pharmacotherapy|September 21, 2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemiasFabio P S Santos, Jorge Cortes
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?Fabio P S Santos, Susan O'Brien
Pageof 5